Better Health for All

ResMed's core products, such as CPAP and PAP therapy, demonstrate significant positive health impacts. A meta-analysis showed CPAP therapy lowers mortality by 37% in sleep apnea patients, with a 55% reduction in cardiovascular-related death

. PAP therapy also led to a 31% reduction in hospitalizations and a 23% decrease in ER visits for OSA patients with comorbid insomnia and type 2 diabetes . The company's digital health ecosystem, including cloud-connected devices, has improved CPAP therapy compliance to 87% . ResMed's mission is to help people sleep better, breathe better, and live healthier lives, having improved over 165 million lives in the past year . The company actively addresses the public health crisis of untreated sleep apnea, which is linked to various chronic conditions . There is no evidence of any products or activities with negative health outcomes.

Fair Money & Economic Opportunity

ResMed Inc. does not engage in or promote financial services or economic opportunity initiatives.

The company's core business is healthcare, focusing on medical devices and software solutions, which does not involve providing fair financial products or services, accessible lending, or microloans. Consequently, ResMed Inc. does not offer lending or deposit services, manage customer finance data, or provide debt products to consumers.

Fair Pay & Worker Respect

ResMed reported a CEO pay ratio of 235:1.

, with the CEO's total compensation at nearly $13.9 million and the median employee's total annual pay at $59,197. Approximately 16% of the total workforce in Australia is organized , and employees in France and parts of Germany are represented by Work Councils. The company's Total Recordable Injury Frequency Rate (TRIFR) is 1.00 per 200,000 hours , and no fatalities were recorded. Voluntary employee turnover averages 14.25%. Contingent workers represent 18.8% of the total workforce.

Fair Trade & Ethical Sourcing

ResMed Inc. demonstrates a commitment to ethical sourcing and supply chain transparency, particularly concerning conflict minerals (tantalum, tin, tungsten, and gold). In 2023, the company conducted due diligence, partnering with a third-party consultant to collect and analyze information from suppliers, achieving a 94% response rate for applicable sourced parts.

Of the 450 smelters and refiners identified, 52% were recognized as conformant or engaged with the Responsible Minerals Initiative. ResMed's Supplier Manual outlines expectations for environmental performance, including compliance with RoHS and REACH, and rewards suppliers with ISO 14001 certification. The company acknowledges challenges in obtaining complete multi-tiered supply chain information and relies on industry efforts and third-party audits to improve transparency.

Honest & Fair Business

ResMed reported zero monetary losses from legal proceedings associated with bribery, corruption, anti-competitive behavior, false marketing, and market-related non-compliance for 2023-2025.

The company also received some notices of minor nonconformance from regulatory authorities, which were identified and corrected by internal audit. ResMed prohibits all forms of bribery and facilitation payments and complies with global anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, OECD, UK Bribery Act, and Brazilian Anti-Corruption Act. It provides online and face-to-face training and extends ethical expectations to third parties through a Global Third Party Code of Conduct that includes anti-bribery, corruption, ethical due diligence, and risk mitigation. The company has a comprehensive whistleblower policy, including a 24/7 anonymous and confidential global disclosure hotline (EthicsPoint) managed by an independent third party, with country-specific phone numbers and translators, supported by a strict non-retaliation policy. The Board of Directors has 7 members, and a majority (at least 57.14%) must qualify as independent under NYSE listing standards.

Kind to Animals

ResMed conducts animal testing for product development and clinical research, as required by regulatory agencies like the FDA.

The company's policy is to employ the 3Rs approach (Replacement, Reduction, and Refinement) to animal studies whenever possible. They take all practicable steps to ensure animal care and welfare meet the required standard specified by ISO 10993-2:2022. This policy prohibits discretionary testing, but legal mandates still necessitate animal studies.

No War, No Weapons

ResMed Inc. is a medical equipment company focused on healthcare, with no significant involvement in military or defense sectors.

Its core business operations do not involve the production or supply of weapons, arms components, or military goods. The company has not been identified as a manufacturer of offensive weapons systems, nor does it produce prohibited weapons. While ResMed engages in medical contracts with the Department of Veterans Affairs and Department of Defense, these are solely for healthcare purposes and do not involve military operations or weaponry. The company was also awarded a $31.98 million contract by the U.S. Department of Health and Human Services for ventilators during the COVID-19 pandemic, an effort focused on healthcare solutions.

Planet-Friendly Business

ResMed achieved 100% renewable electricity across its global operations in 2023.

The company's Environmental Management System is ISO 14001:2015 certified, which systematically reduces environmental impacts and includes efforts in packaging waste diversion, material mass reduction, and energy efficiency improvements.

Respect for Cultures & Communities

ResMed has formal partnerships with at least four local community groups or community-serving organizations, including the San Diego Food Bank, The Center in San Diego, the Nova Scotia Lung Association, and the American Sleep Association.

No cultural appropriation incidents have been reported. The company does not have a specific cultural impact assessment protocol, which is consistent with its business operations not typically impacting cultural contexts. Free, Prior and Informed Consent (FPIC) processes are not applicable to the company's operations. No cultural site disruptions have been reported, and the company's operations do not appear to be near such sites. Furthermore, no cultural incident response framework is mentioned, and no cultural incidents have been reported.

Safe & Smart Tech

ResMed reported zero material security events between 2023 and 2025

and is not aware of any known risks from cybersecurity threats that have materially affected it. The company maintains a comprehensive set of privacy and security certifications, including HITRUST, ISO 27001, SOC-2, Japan’s P-Mark, France’s HDS, and the UK NHS Data Security and Protection Toolkit. ResMed complies with an extensive list of global and regional data protection laws, such as HIPAA, HITECH Act, SEC Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure Rule, FDA Final Cybersecurity in Medical Devices Guidance, European and UK GDPR, China PIPL, India DPDPA, Australian Privacy Act, CCPA, and the EU AI Act. ResMed has established an AI Governance Council, chaired by its CCO, and applies a full lifecycle approach to data and digital product governance, including AI and machine learning solutions. The company uses encryption during transmission and storage, including end-to-end encryption, with strong encryption for cellular data, and stores data in encrypted form. Its products and services are guided by privacy and security by design principles, with devices collecting only the information necessary for therapy management. Users control who accesses their sleep reports and can manage data sharing preferences, supported by a Data Subject Request Automation tool. ResMed anonymizes data for large-scale research and shares identifiable data or data with insurers only with explicit consent. The company conducts regular third-party security and privacy assessments, including penetration tests and attack simulations on critical products. ResMed also has a vulnerability disclosure program with reporting procedures, a review process, and a coordinated disclosure timeline, aiming to respond to status inquiries within 10 business days.

Zero Waste & Sustainable Products

The company's Singapore site achieved a recycling rate of approximately 90% in 2025, and its Sydney site diverted 100% of product waste from landfill in 2025.

All AirSense 10 and AirSense 11 cartons and shippers are fully recyclable, and device carton packaging solutions contain at least 60% recycled content. The company has implemented over 10 waste reduction initiatives, including recycling 19.89 tons of foam, saving 336 metric tons of cardboard annually by reducing AirSense 11 carton size, and saving 4.46 tonnes of plastic in European warehousing and logistics. It recycled 146.59 tons of hazardous waste in FY25 and monitors both hazardous and non-hazardous waste. A 72% repair rate was achieved for over 94,000 devices across 63 product types globally, supported by implemented design-for-repair and design-for-disassembly principles. The company has company-wide targets to divert product waste from landfill by 2026 and design products for circularity by 2030, with a specific goal for the Sydney site to achieve zero waste to landfill by 2030. Environmental expectations are clearly set out for all suppliers in the Supplier Manual. A globally compliant labeling strategy displays recycling information on AirSense 10 and AirSense 11 cartons and shippers. There have been no material non-compliance notices during 2025 and no equivalent notices from other agencies for production plant inspections in the last four years (2022-2025).